Immediate access to certified Active Pharmaceutical Ingredients (APIs) supporting metabolic, endocrine, and immunological programs in regional production plants across Tashkent and the wider CIS region.
Understanding the economic shift driving pharmaceutical autonomy, the Tashkent Pharma Park development, and the critical need for resilient peptide API supply corridors.
Uzbekistan has accelerated domestic drug manufacturing through presidential decrees aimed at increasing domestic pharmaceutical production to 80% of local consumption. While secondary packaging and small molecule synthesis have matured rapidly, high-barrier bio-macromolecules—specifically chemically synthesized generic peptides—represent a key technological void that local formulators must resolve to maintain sovereign medical safety.
The state-backed Tashkent Pharma Park and dedicated Free Economic Zones (FEZs) in Syrdarya and Samarkand are welcoming domestic fill-finish vial lines and pre-filled syringe (PFS) facilities. Our generic peptide APIs supply direct raw chemical substance inputs into these specialized sterile facilities, satisfying high-standard sterile crystallization and lyophilized powder manufacturing prerequisites.
The demographic landscape of Uzbekistan and Central Asia faces growing incidence rates of Type-2 diabetes, cardiovascular complications, metabolic syndromic states, and chronic pulmonary diseases. Our portfolio provides Uzbek drug enterprises with dependable inputs for GLP-1 receptor agonists, thymic host-defense peptide modulators, and tissue-reparative molecules crafted for localized regional pathology demands.
How our Hangzhou chemical synthesis facilities bypass intermediate supply chokepoints and offer cost, purity, and capacity assurances directly to Uzbek manufacturers.
By producing protected Fmoc/Boc amino acids, specialized coupling reagents (HBTU, HATU, PyBOP), and pseudo-proline dipeptides in-house or under dedicated contract upstream channels, Thinheal isolates Uzbek clients from global intermediate price surges and delivery delays. We guarantee uninterrupted chain propagation even for long sequences surpassing 30 to 45 amino acid residues.
Combining microwave-assisted solid-phase peptide synthesis (SPPS) for sequence assembly with liquid-phase peptide synthesis (LPPS) fragment condensation techniques allows us to produce commercial-scale peptide quantities up to multi-hundred kilogram and metric-ton batches without stereochemical racemization or substantial epimer contamination.
Direct logistical channels via dedicated air transport routes from Hangzhou and Shanghai straight into Islam Karimov Tashkent International Airport (TAS), alongside railway cargo services connecting Xi'an to Tashkent, assure validated uninterrupted cold-chain handling (-20°C / 2-8°C with digital dataloggers) with clear customs transit protocols.
Setting the highest analytical benchmark for peptide chemistry, aligned fully with USP, Ph. Eur., and State Pharmacopoeia of Uzbekistan protocols.
High-resolution electrospray ionization mass spectrometry (HR-ESI-MS), MALDI-TOF, and tandem MS/MS fragmentation analysis to verify exact sequence arrangement, peptide mass mapping, and absence of sequence deletions.
Orthogonal reverse-phase HPLC with dual wavelength and gradient elution tracks all D-amino acid enantiomers, diastereomeric variants, beta-aspartyl rearrangements, and desamido impurities to ensure active purity consistently >99%.
Rigorous ion chromatography and Headspace GC ensure trifluoroacetate (TFA) exchange to biocompatible acetate or hydrochloride forms, alongside trace volatile solvent levels well within ICH Q3C Class II and Class III thresholds.
Chromogenic LAL assays certify endotoxins below 0.05 EU/mg. Long-term (25°C/60% RH) and accelerated (40°C/75% RH) ICH Q1A stability data packs are cataloged for swift local dossier evaluation and registration.
Leveraging the World Intellectual Property Organization (WIPO) and Eurasian Patent Organization (EAPO) environments for proactive generic formulation rollout.
While primary synthesis patents for breakthrough incretin mimetics remain heavily guarded in Western territories, emerging markets like Uzbekistan operate under dynamic local intellectual property provisions. We provide Uzbek legal and pharmaceutical teams with clear Freedom-to-Operate (FTO) guidance and non-infringing synthetic routes for early generic development.
Registration with the State Center for Expertise and Standardization of Medicines, Medical Devices and Medical Equipment requires meticulous validation packages. We prepare complete Module 3 Open Parts (Drug Master Files), synthesis development histories, analytical cross-validations, and batch impurity qualification records to accelerate drug product licensing.
Transitioning peptide APIs into high-throughput sterile lyophilization vials or multi-dose cartridge pens can challenge formulation engineers. Our regional desk and senior peptide scientists deliver hands-on formulation troubleshooting, reconstitution buffering advice, and stability preservation consulting directly to your R&D personnel.
Immediate answers to technical inquiries regarding customs clearance, analytical validation, and batch scale-up.
We supply full commercial and technical documentation, including Certificates of Analysis (CoA) matching Uzbek state pharmacopeial monograph guidelines, MSDS, batch production protocols, and Drug Master Files (DMF) formatted in CTD Module 3 style. We liaise directly with regional import agents in Tashkent to guarantee seamless transit approval through customs border inspections.
While default chemical synthesis frequently leaves peptide materials as trifluoroacetate (TFA) salts, therapeutic injectables typically require acetate, hydrochloride, or sodium salt formulations. Thinheal performs validated ion-exchange chromatography steps, achieving residual TFA levels below 0.1% or undetectable limits according to target formulation requirements.
For catalog generic peptide APIs in stock, materials ship under active temperature monitoring within 5 business days. Custom process scale-up or multi-kilogram commercial manufacturing runs typically require 4 to 8 weeks, inclusive of synthesis, dual purification stages, lyophilization cycles, and comprehensive batch release testing.
Yes. Uzbekistan experiences wide climatic variation (Zone II / Zone IVa parameters). We design robust lyophilization cakes with customized moisture barriers, and supply both accelerated stability data and recommended excipient compatibility profiles (e.g., mannitol, trehalose, phenoxyethanol) to preserve molecule integrity under local climatic stresses.
Expanded peptide active ingredients supporting oncology, neurology, reproductive medicine, and next-generation obesity formulations.
Partner with Hangzhou Thinheal Pharma-Tech Co., Ltd. for seamless peptide API sourcing, multi-ton commercial dependability, comprehensive technical dossiers, and dedicated CIS regional assistance.
Send Inquiry Now
Thin